Between-hospital variation in mortality and survival after glioblastoma surgery in the Dutch Quality Registry for Neuro Surgery

Dutch Soc Neurosurg, Philip C. De Witt Hamer*, Vincent K. Y. Ho, Aeilko H. Zwinderman, Linda Ackermans, Hilko Ardon, Sytske Boomstra, Wim Bouwknegt, Wimar A. van den Brink, Clemens M. Dirven, Niels A. van der Gaag, Olivier van der Veer, Albert J. S. Idema, Alfred Kloet, Jan Koopmans, Mark ter Laan, Marco J. T. Verstegen, Michiel Wagemakers, Pierre A. J. T. Robe

*Corresponding author for this work

    Research output: Contribution to journalArticleAcademicpeer-review

    7 Citations (Scopus)
    118 Downloads (Pure)

    Abstract

    Purpose Standards for surgical decisions are unavailable, hence treatment decisions can be personalized, but also introduce variation in treatment and outcome. National registrations seek to monitor healthcare quality. The goal of the study is to measure between-hospital variation in risk-standardized survival outcome after glioblastoma surgery and to explore the association between survival and hospital characteristics in conjunction with patient-related risk factors. Methods Data of 2,409 adults with first-time glioblastoma surgery at 14 hospitals were obtained from a comprehensive, prospective population-based Quality Registry Neuro Surgery in The Netherlands between 2011 and 2014. We compared the observed survival with patient-specific risk-standardized expected early (30-day) mortality and late (2-year) survival, based on age, performance, and treatment year. We analyzed funnel plots, logistic regression and proportional hazards models. Results Overall 30-day mortality was 5.2% and overall 2-year survival was 13.5%. Median survival varied between 4.8 and 14.9 months among hospitals, and biopsy percentages ranged between 16 and 73%. One hospital had lower than expected early mortality, and four hospitals had lower than expected late survival. Higher case volume was related with lower early mortality (P = 0.031). Patient-related risk factors (lower age; better performance; more recent years of treatment) were significantly associated with longer overall survival. Of the hospital characteristics, longer overall survival was associated with lower biopsy percentage (HR 2.09, 1.34-3.26, P = 0.001), and not with academic setting, nor with case volume. Conclusions Hospitals vary more in late survival than early mortality after glioblastoma surgery. Widely varying biopsy percentages indicate treatment variation. Patient-related factors have a stronger association with overall survival than hospital-related factors.

    Original languageEnglish
    Pages (from-to)313-323
    Number of pages11
    JournalJOURNAL OF NEURO-ONCOLOGY
    Volume144
    Issue number2
    DOIs
    Publication statusPublished - Sep-2019

    Keywords

    • Glioblastoma
    • Neurosurgical procedures
    • Quality of health care
    • Outcome assessment
    • Mortality
    • Survival
    • NEWLY-DIAGNOSED GLIOBLASTOMA
    • UNITED-STATES
    • TEMOZOLOMIDE ERA
    • ELDERLY-PATIENTS
    • PHASE-III
    • CARE
    • PATTERNS
    • RESECTION
    • OUTCOMES
    • GLIOMA

    Cite this